Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.
-
Upload
shanna-hicks -
Category
Documents
-
view
224 -
download
3
Transcript of Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.
![Page 1: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/1.jpg)
Antidepressant Pharmacotherapy
Charles DeBattista, MD
Stanford University
![Page 2: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/2.jpg)
Outline
Phenomenology of MDD• Risk Factors• Co morbid conditions• EconomicsPathophysiology• Monoamines• Stress/Neurotrophic factors•Classes of Agents• SSRIs• TCAs• SNRIs• MAOIs• Other AgentsFuture Classes of Drugs
![Page 3: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/3.jpg)
Teaching Points
– Our knowledge of the pathophysiology of depression is incomplete
– Limitation of current treatment include slow onset, tolerability, and lack of adequate efficacy for many patients
– Each class of antidepressants has unique risks and benefits
![Page 4: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/4.jpg)
Pre-Lecture ExamQuestion 1
The most common side effects early in the course of SSRI treatment leading to discontinuation is
1. GI upset
2. Loss of libido
3. Headache
4. Weight gain
![Page 5: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/5.jpg)
Question 2
The most common cause of death in TCA overdose is
1. Arrhythmia
2. Seizure
3. Congestive heart failure
4. Stroke
![Page 6: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/6.jpg)
Question 3
Noradrenergic side effects of antidepressants may include
1. Sedation
2. Weight gain
3. Tachycardia
4. All of the above
![Page 7: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/7.jpg)
Question 4
The neurotrophic hypothesis of depression suggests1. Depression is related to loss of neurotrophic support
2. Antidepressants increase neurotrophic factors such as BDNF
3. Depression is associated with a progressive loss of volume in areas such as the hippocampus
4. All of the above
![Page 8: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/8.jpg)
Question 5
Foods that are likely be problematic for patients on MAOIs include
1. Soy sauce
2. American Cheese
3. Pasteurized Beer
4. All of the above
![Page 9: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/9.jpg)
MAJOR DEPRESSION: DSM-IV DIAGNOSTIC CRITERIA
– Depressed mood most of the day, nearly every day– Diminished interest or pleasure in activities
– Major change in appetite or weight– Insomnia or hypersomnia– Psychomotor agitation or retardation– Fatigue or loss of energy– Feelings of worthlessness or excessive or inappropriate guilt– Diminished ability to think or concentrate, or indecisiveness– Recurrent thoughts of death, dying, or suicide
APA Diagnostic and Statistical Manual. 1994
![Page 10: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/10.jpg)
Lithium
“Black bile”
1900
ECT TCAs SSRIs
PharmacologicRefinements
1st century ’’30s30s ’’80s80s ’’90s90s ’’40s40s ’’50s50s ’’60s60s
MAOIs
Kaplan HI, Sadock BJ. In: Pocket Handbook of Psychiatric Drug Treatment. 1996.
Developments in Medical Treatment of Depression
’’70s70s
Heterocyclics
![Page 11: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/11.jpg)
Kessler RC et al. Arch Gen Psychiatry. 1994;51:8-19.Depression Guideline Panel. AHCPR publication 93-0550. 1993.Greenberg PE et al. J Clin Psychiatry. 1993;54:405-418.
Epidemiology of Depression• 17% lifetime prevalence of a major
depressive episode• Up to 15% of patients with major depressive
disorder requiring hospitalization commit suicide• Total annual cost to society – $44 billion, 55% of
which is due to lost productivity
![Page 12: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/12.jpg)
•Risk factor Association•Gender Twice as likely in women
•Age Peak age of onset is 20–40 years
•Family history 1.5 to 3.0 times higher risk
•Marital status Higher rates in separated, widowed,
and divorced persons
• Married males lower than never married
• Married females higher than never married
RISK FACTORS FOR MAJOR DEPRESSION
Blazer. Am J Psychiatry. 1994Stahl. Essential Psychopharmacology. 1996
![Page 13: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/13.jpg)
Euthymia
Symptoms
Syndrome
Treatment phases
Prog
ression
to disorder
Acute(6–12 wk)
Continuation(4–9 mo)
Maintenance( 1 yr)
TimeTime
Incr
ea
sed
Incr
ea
sed
sev
eri
tys
eve
rity RelapseRelapse
ResponseResponse
RemissionRemission
RecurrenceRecurrenceRelapseRelapse
Kupfer DJ. J Clin Psychiatry. 1991;52(suppl 5):28.
+
+
Phases of Treatment for Depression
![Page 14: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/14.jpg)
Patients with Major Depression
Keller MB, Boland RJ. Biol Psychiatry. 1998;44:348-360.
0
10
20
30
40
50
1 2 4 5 6 7 10 12Weeks since recovery3 or more previous episodes
0 - 3 previous episodes
Cumulative Probability of Relapse%
rel
apse
d
![Page 15: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/15.jpg)
DepressionImpact vs. Other Chronic Medical
Conditions
+ = Worse Functioning in Depression
Wells, JAMA, 1989
Hypertension + + + + + +
Diabetes + + + + + +
Advanced CAD + + +
Arthritis + + + + + +
Medical Physical Social Role Bed Current HealthBodily PainCondition Function Function Function Days Perception
![Page 16: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/16.jpg)
Lost productivity—55%
Outpatient care—6%
Suicide—17%
Inpatient care—19%
Pharmaceuticals—3%
Greenberg PE et al. J Clin Psychiatry. 1993;54:405-418.
Economics of Depression—Total Annual Cost ~$44 Billion
![Page 17: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/17.jpg)
Monoamines, and Receptors:Proposed Mechanisms of Action of Antidepressants
Monoamines, and Receptors:Proposed Mechanisms of Action of Antidepressants
• Blockade of neuronal re-uptake of monoamines
• Adaptive down-regulation of receptors
• Blockade of serotonin-2 receptors
• Inhibition of MAO
• Post-synaptic cascades giving rise to neuroadaptive changes
• Hormonal effects of antidepressants
![Page 18: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/18.jpg)
MONOAMINE HYPOTHESIS
Depression is caused by a deficiency of
SEROTONIN,SEROTONIN,NOREPINEPHRINE,NOREPINEPHRINE,
or BOTHor BOTH
Every approved antidepressant can increase
serotonin neurotransmission,
norepinephrine neurotransmission,
or both
Every approved antidepressant can increase
serotonin neurotransmission,
norepinephrine neurotransmission,
or both
![Page 19: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/19.jpg)
Neurotransmitter Regulation of Mood, Cognition, and Behavior
Stahl SM. Essential PsychopharmacologyFoote Sl, Pharmacology and physiology of central noradrenergic systems, Psychopharmacology, 1995
Norepinephrine
Serotonin
Mood
Anxiety
Alertness
Drive
Attention Pleasure/Reward
Motivation
Dopamine
Obsessive Compulsive Disorder
![Page 20: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/20.jpg)
Affinities (Ki) of Antidepressants for Monoamine Transporters and Receptors
Ki = inhibition constant, nmol/LOwens MJ et al. J Pharmacol Exp Ther. 1997;283:1305-1322.
Serotonin Norepinephrine
Desipramine 163 3.5
Fluoxetine 20 2186
Imipramine 20 142
Nefazodone 549 713
Paroxetine .83 328
Sertraline 3.3 1716
Venlafaxine 102 1644
![Page 21: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/21.jpg)
Neurotrophic Hypothesis of Depression
• Depression is associated with loss of neurotrophic support in key brain regions such as the hippocampus
• All effective antidepressant therapies increase neurotrophic support in specific brain regions through secondary cascade systems
![Page 22: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/22.jpg)
![Page 23: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/23.jpg)
Limitations of Current Antidepressants
• Slow Onset
• Incompletely effective
• Multiple Side effects
• Non-generics are costly
• Potential for drug interactions
![Page 24: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/24.jpg)
Antidepressant Adverse Effects
MetabolicWeight changes
UrogenitalErectile dysfunction, ejaculation disorder, anorgasmia, priapism
CardiacOrthostasis,
hypertension, heart block
CNSDizziness, memory
impairment, sedation, light-headedness,
somnolence, nervousness, insomnia, headache,
tremorGI
Nausea, constipation, vomiting, dyspepsia,
diarrhea
Autonomic NSDry mouth, urinary
retention, constipation, blurred vision, sweating
![Page 25: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/25.jpg)
Current Depression Treatment Options
• Pharmacologic– Antidepressant medications
• Nonpharmacologic– Psychotherapy
• Cognitive behavioral therapy• Interpersonal therapy• Psychodynamic therapy
– Electroconvulsive therapy– Phototherapy– Rapid transcranial magnetic stimulation (RTMS) – Vagus nerve stimulation
Depression Guideline Panel. Depression in Primary Care: Vol 1. Detection and Diagnosis. Clinical Practice Guideline No. 5, 1993
![Page 26: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/26.jpg)
New Generation Antidepressants
• Fluoxetine (Prozac) 1988• Bupropion (Wellbutrin IR) 1989• Sertraline (Zoloft) 1992• Paroxetine (Paxil) 1993• Venlafaxine (Effexor) 1994• Fluvoxamine (Luvox) 1994• Nefazodone (Serzone) 1995• Mirtazapine (Remeron) 1996• Citalopram (Celexa) 1998• Escitalopram (Lexapro) 2003• Duloxetine (Cymbalta) 2004• Selegiline transdermal (Emsam) 2006• Desvenlafaxine (Pristiq) 2008
![Page 27: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/27.jpg)
The Utility of Antidepressant Therapy
• 50-60% of depressed patients respond to any given antidepressant, and 80% to 95% respond to one or a combination of therapeutic interventions if multiple therapies are tried (Thase and Rush, Psychopharmacology: Fourth Generation of Progress, 1995).
• Half of depressed patients will experience a remission within 6 months of an index case of depression, and perhaps more than 75% will remit by 2 years (Keller et al, Arch Gen Psychiatry, 1992).
• Antidepressants appear effective in reducing relapse rates
![Page 28: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/28.jpg)
Limitations of Antidepressant Therapy
• The percentage of patients who remain well during the18-month period following successful treatment for depression is disappointingly low: 19% to 30% in one study (Shea, et al. Arch Gen Psychiatry, 1992).
• At least 20% of treatment naïve patients fail to achieve remission even 4 sequential treatment trials with monotherapy and combinations (Rush et al, NEJM, 2006)
• More than half of patients fail to ever attain remission in acute trials, and those that do commonly may not sustain remission
![Page 29: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/29.jpg)
Clinical Correlates of Enhanced Neurotransmission
Serotonergic side effects• GI upset
• Sexual dysfunction
• Sleep disturbance
With long-term use
• Weight gain
• Suppression of dopamine neurotransmission may lead to:
– Decrease in ability to experience pleasure– Apathy and decreased motivation– Decreased attention and cognitive
slowing
Noradrenergic side effects
• Tremor
• Tachycardia
Dopaminergic side effects
• Psychomotor activation
• Aggravation of psychosis
Stahl SM. Essential PsychopharmacologyRichelson E., Pharmacology of antidepressants, Mayo Clin Proc, 1994Kapur, Serotonin-dopamine interaction and its relevance to schizophrenia, Am J Psychiatry, 1996
![Page 30: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/30.jpg)
Deficiencies in Current Antidepressant Therapy
• Slow onset of action
• Inadequate response for many patients
• Expense
• Toxicity
• Stigma
![Page 31: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/31.jpg)
Common Features of Antidepressants
• All work on Monoamines• All take 3-8 weeks to be maximally
effective• All have equivalent response rates (50-70%
and remission rates (35-50 %)• All have serotonin or NE side effects• Placebo drug differences are greatest in
more severe depression
![Page 32: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/32.jpg)
The Selective Serotonin Reuptake Inhibitors
• Represent over 60-70 % of new prescriptions in MDD
• Easy to use and dose
• High Therapeutic Index
• Broad spectrum of activity
![Page 33: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/33.jpg)
Current SSRIs
• Fluoxetine (Prozac)
• Sertraline (Zoloft)
• Paroxetine (Paxil)
• Fluvoxamine (Luvox)
• Citalopram (Celexa)
• Escitalopram (Lexapro)
![Page 34: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/34.jpg)
Indications (FDA)
• MDD
• OCD
• Panic
• Social Anxiety
• PTSD
• PMDD
![Page 35: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/35.jpg)
Fluoxetine
![Page 36: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/36.jpg)
Actions of SSRIs
![Page 37: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/37.jpg)
Selective Serotonin Reuptake Inhibitors: Prozac
Pros• Safe• Easy dosing• Few side effects• Broad Spectrum of
activity
Cons• GI/Sexual AEs• Slow• Moderate efficacy• Cost
![Page 38: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/38.jpg)
In Vitro P450 Inhibition by SSRIs
Drug 1A2 2C9 2C19 2D63A
Citalopram 0/+ 0 0 +0
Fluoxetine + ++ +/++ ++++/++
Fluvoxamine +++ ++ +++ +++
Paroxetine + + + ++++
Sertraline + + +/++ ++
![Page 39: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/39.jpg)
Cytochrome P450 (CYP450):Enzymes and Selected Substrates
Theophylline Phenytoin Codeine AntihistaminesWarfarin Warfarin Venlafaxine Calcium channel
blockersAntipsychotics Amitriptyline Trazodone CarbamazepineBenzodiazepines Clomipramine Risperidone CisaprideFluvoxamine Omeprazole Haloperidol Corticosteroids
Codeine Cyclosporine -blockers Fentanyl
Protease inhibitorsStatinsTriazolobenzodiazepine
1A2 2C 2D6 3A41A2 2C 2D6 3A4
![Page 40: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/40.jpg)
Common SSRI Side Effects• Central nervous system (CNS)
Activating SedatingInsomnia SomnolenceAnxiety FatigueAgitationNervousnessTremorsDizziness
• Gastrointestinal (GI) side effects– Nausea, vomiting, abdominal pain, diarrhea, constipation
• Sexual dysfunction
• Weight changes
![Page 41: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/41.jpg)
Gastrointestinal Side Effects with SSRIs
• Similarities > differences
• Adaptation: 1-2 weeks
• May be managed by dose reduction
![Page 42: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/42.jpg)
Antidepressant-Induced Sexual Dysfunction
Most patients will not complain of antidepressant-induced sexual dysfunction early in treatment because of low libido caused by the depression itself
The incidence of antidepressant-induced sexual dysfunction was originally thought to be negligible because physicians relied on spontaneous reporting of sexual problems
• We now know that the incidence of antidepressant-induced sexual dysfunction is over 50% for most of the SSRIs and newer agents
![Page 43: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/43.jpg)
The Incidence of Sexual Dysfunction Among SSRIs
Montejo-Gonzalez AL et al. J Sex Marital Ther. 1997;23(3):176-194
0
10
20
30
40
50
60
70
Fluoxetine Sertraline FluvoxamineParoxetine
Per
cen
t o
f P
atie
nts
54% 56% 59%65%
![Page 44: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/44.jpg)
1Fava et al, 2000; 2Data on file: Organon Inc.; 3Feiger, 1999; 4Data on file: Bristol-Myers Squibb Company; 5Mackle & Kocsis. ACNP, 1998; 6Data on file: Forest Pharmaceuticals, Inc.; 7Weihs et al. APA, 2000 (Poster presentation)
Weight Gain Associated with Long-Term (6-24 Months) Use of Antidepressants in Double-Blind Studies
Sertraline1 1.7 4Fluoxetine1 -2.2 7Paroxetine1, 2 6.0 26Mirtazapine2 4.0 13Nefazodone3, 4 1.2 8Citalopram5, 6 3.0 5Bupropion7 -2.6N/A
Mean Weight Gain 7% Weight Gain
(lbs) (%)
![Page 45: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/45.jpg)
Weight Change Associated with Antidepressants
• Some associated with weight changes, particularly with long-term treatment
• Weight decreases in short-term treatment may be followed by weight increases in long-term treatment
• Weight increase may be associated with improved appetite (treatment success)
![Page 46: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/46.jpg)
SSRI Discontinuation Syndrome• Dizziness, vertigo, ataxia
• Nausea
• Sleep disturbances
• Flu-like symptoms
• Paresthesia
• Anxiety/agitation/irritability
• Crying spells/irritability
Schatzberg AF et al. J Clin Psychiatry. 1997;58(suppl 7):5-10
![Page 47: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/47.jpg)
The Tricyclic Antidepressants
• Dominated MDD treatment from 1958 to1988• Might be more effective than SSRIs in
melancholic depression • Need for titration to reach a therapeutic dose• Numerous side effects• Highly lethal in overdose
![Page 48: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/48.jpg)
TCA Agents
Tertiary Amines TCAs
• Imipramine (Tofranil)
• Amitriptyline (Elavil)
Secondary Amine TCAs
• Desipramine (Norpramin)
• Nortriptyline (Pamelor)
![Page 49: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/49.jpg)
TCA indications
• MDD
• Panic
• Enuresis
• OCD (Clomipramine)
• Also used in PCP setting for pain, migraine prevention, sleep)
![Page 50: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/50.jpg)
Imipramine
![Page 51: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/51.jpg)
TCA Actions
![Page 52: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/52.jpg)
Remission Rates for TCAs, SSRIs, and Placebo
In endogenous depression or major depression with melancholic features
![Page 53: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/53.jpg)
TCA Side Effects
• Dry mouth, constipation, blurred vision, urinary retention,
• Hypotension
• Sedation, Wt gain
• Sexual A Es
• Cardiac conduction AEs
![Page 54: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/54.jpg)
The Monoamine Oxidase Inhibitors (MAOIs)
• Oldest class of antidepressants
• More rarely used currently: treatment resistant depression
• Potential for serious drug interactions (Serotonin Syndrome)
• Tyramine Pressor effects (Hypertensive crisis)
![Page 55: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/55.jpg)
MAOIs
• Trandermal Selegeline (Emsam)
• Phenelzine (Nardil)
• Tranylcypramine (Parnate)
![Page 56: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/56.jpg)
Selegiline
![Page 57: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/57.jpg)
Selegiline Mechanism
![Page 58: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/58.jpg)
MAOI Side Effects
• Hypotension
• Sexual AE s
• Weight gain
• Sedation/activation
![Page 59: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/59.jpg)
MAOI Drug interactions
• Serotonergic drugs (SSRIs, clomipramine, meperidine, tramadol); Serotonin syndrome
• Sympathomimetics and Tyramine Foods: Hypertensive crisis
![Page 60: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/60.jpg)
High Tyramine Food Examples
• Aged cheeses (stilton, blue)
• Dried sausage/salami
• Pickled herring
• Soy sauce, tofu
• Fava bean pods
• Marmite, brewers yeast
• Tap beer, chianti
![Page 61: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/61.jpg)
SNRIs; Venlafaxine, Desvenlafaxine, Duloxetine
• Similar to TCAs in mechanism but without the anti ACH, anti-H, and anti-alpha
• Useful in some pain syndromes• May be useful in stress incontinence• Appear useful in vasomotor symptoms in
menopause• May be more effective than SSRIs in serious
depression
![Page 62: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/62.jpg)
Venlafaxine
![Page 63: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/63.jpg)
Remission Rates (HAM-D<8):venlafaxine-SSRI Pooled Studies
(%)
![Page 64: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/64.jpg)
SNRI side effects
• GI
• Sexual
• Activation/somnolence
• Hypertension/tachycardia
• Urinary retention
• Dry mouth, constipation
![Page 65: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/65.jpg)
Mirtazapine (Remeron)
• Indicated in MDD only
• May be effective in augmenting SSRIs, SNRIs
• Highly sedating
• Associated with weight gain
• Safe in overdose
• Few sexual AEs
![Page 66: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/66.jpg)
Mirtazapine
![Page 67: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/67.jpg)
Mirtazapine Mechanism
![Page 68: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/68.jpg)
0
5
10
15
20
25
30
1 2 3 4 6Weeks
%
mirtazapine (n=60)
fluoxetine (n=63)*
* p < 0.05ITT LOCF
Mirtazapine versus FluoxetineRemission rates (HAMD<7)
Wheatley et al., 1998
*
![Page 69: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/69.jpg)
5HT-2 Antagonists (Nefazodone, Trazodone)
• Indicated in MDD
• Nefazodone associated with hepatoxicity
• May be useful in GAD
• Trazodone commonly used as a hypnotic
• Perceived as less robust antidepressants
![Page 70: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/70.jpg)
Trazodone
![Page 71: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/71.jpg)
5HT2 Antagonist AEs
• Sedation
• Weight gain
• Orthostatic hypotension
• Priapism (trazodone)
![Page 72: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/72.jpg)
Bupropion
• Indicated in MDD• Indicated in smoking cessation• Commonly used to augment SSRI and
SNRI antidepressants • Not effective in the treatment of anxiety
disorders• Few sexual side effects• Mildly anorexiant
![Page 73: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/73.jpg)
Bupropion
![Page 74: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/74.jpg)
Bupropion Mechanism
• Unknown
• Indirect NE agonist
• Modest DA reuptake in human studies
![Page 75: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/75.jpg)
Bupropion AEs
• CNS activation
• Tremor
• Weight loss
• Few sexual side effects
• Dose related risk of seizure for IR form
![Page 76: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/76.jpg)
Potential Antidepressants
• Glucocorticoid Receptor Antagonists– Mifepristone– Org 34571
• CRF antagonists– - ONO-2333Ms (Ono)– - GSK-561679 (GSK)– - Pexacerfont
• Triple reuptake inhibitors– NS 2359
DOV 216303• Melatonin Agonists
– Agomelatine
![Page 77: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/77.jpg)
Conclusions
• Depression is common
• There are limitations to all current antidepressants but new strategies are evolving.
• There is a need for faster, more effective, better tolerated agents
![Page 78: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/78.jpg)
Post-Lecture ExamQuestion 1
The most common side effects early in the course of SSRI treatment leading to discontinuation is
1. GI upset
2. Loss of libido
3. Headache
4. Weight gain
![Page 79: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/79.jpg)
Question 2
The most common cause of death in TCA overdose is
1. Arrhythmia
2. Seizure
3. Congestive heart failure
4. Stroke
![Page 80: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/80.jpg)
Question 3
Noradrenergic side effects of antidepressants may include
1. Sedation
2. Weight gain
3. Tachycardia
4. All of the above
![Page 81: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/81.jpg)
Question 4
The neurotrophic hypothesis of depression suggests1. Depression is related to loss of neurotrophic support
2. Antidepressants increase neurotrophic factors such as BDNF
3. Depression is associated with a progressive loss of volume in areas such as the hippocampus
4. All of the above
![Page 82: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/82.jpg)
Question 5
Foods that are likely be problematic for patients on MAOIs include
1. Soy sauce
2. American Cheese
3. Pasteurized Beer
4. All of the above
![Page 83: Antidepressant Pharmacotherapy Charles DeBattista, MD Stanford University.](https://reader035.fdocuments.in/reader035/viewer/2022062407/56649e7f5503460f94b8372c/html5/thumbnails/83.jpg)
Answers to Pre- and Post-Lecture Exams
1. 1
2. 1
3. 3
4. 4
5. 1